Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Johnson & Johnson (Pty) Ltd

http://www.jnjsouthafrica.co.za

Latest From Johnson & Johnson (Pty) Ltd

Medtech Challenged To Build On 2021 Amid Threats Of Recession: Views From Industry Leaders

Strong headwinds beset the medtech industry as 2022 draws to a close, including supply chain, fundraising and labor shortages. However, optimism prevailed among medtech industry leaders discussing EY’s annual Pulse of the Industry medical technology report and related topics at AdvaMed’s 2022 MedTech Conference.

Financing Business Strategies

Medtech Challenged To Build On 2021 Amid Threats Of Recession: Views From Industry Leaders

Strong headwinds beset the medtech industry as 2022 draws to a close, including supply chain, fundraising and labor shortages. However, optimism prevailed among medtech industry leaders discussing EY’s annual Pulse of the Industry medical technology report and related topics at AdvaMed’s 2022 MedTech Conference.

Financing Business Strategies

Updated: Minute Insight: FDA Clears Zimmer Biomet’s Identity Shoulder, ZB Calls It ‘Biggest Shoulder Launch In the Last Five Years’

Zimmer Biomet said on 20 September that the FDA cleared its Identity shoulder system and expects it to be available to US surgeons in the fourth quarter.  

Minute Insights Orthopedics

FTC Launches ‘Colonoscopy’ Into PBM Practices, Including Focus On Consumer Costs, Access

Study will examine how the six largest pharmacy benefit managers in the US handle 10 disease categories. Federal Trade Commissioners unanimously support inquiry after its scope was broadened from an earlier version that drew objections from Republicans.

Pricing Debate Reimbursement
See All

Company Information

UsernamePublicRestriction

Register